Meeting ReportHepatitis C infection, antiviral treatment and mental health: A European expert consensus statement
Introduction
An estimated 170 million people are infected with the hepatitis C virus (HCV) worldwide. HCV infection is the most frequent cause of chronic hepatitis and an important risk factor for liver cirrhosis and hepatocellular carcinoma. There is an increased prevalence of psychiatric co-morbidity in patients with chronic HCV infection and emerging evidence suggests that mental health problems may be associated with the infection itself, possibly mediated by an effect on the central nervous system (CNS). In addition, antiviral combination therapy with PegIFNα and ribavirin is often associated with significant psychiatric side effects, such as depression, fatigue, insomnia, anxiety, cognitive disturbances [1], [2] or suicide attempts, which represent the worst possible complication of severe depressive syndromes [3]. Mental health problems during antiviral treatment have a strong impact on quality of life, may reduce treatment compliance and are risk factors for treatment failure [4], [5], [6]. Research over recent years has sought to increase knowledge about the frequency, course, and pathophysiology of mental health problems during chronic HCV infection and antiviral therapy with PegIFNα and ribavirin. Different management strategies for the acute treatment or for the prevention of psychiatric problems have been developed to avoid dose reduction or treatment discontinuation. However, to date there has not been an international, interdisciplinary consensus regarding the current knowledge of mental health problems during HCV infection and treatment-related psychiatric problems. At the 2011 EASL meeting, the European liver patient’s organization (ELPA) initiated a European expert consensus conference to review the current available scientific data on HCV and treatment-related psychiatric effects, in order to produce recommendations for the psychiatric management of patients before, during and after hepatitis C treatment.
Section snippets
Methods
The European expert consensus group consisted of four hepatologists, five clinical psychiatrists and/or neurobiologists, from Europe, and a member of ELPA. Consensus was based on current available clinical trials and other evidence published in the English language to March 2011, and the clinical experience of the consensus group. The following questions were discussed: (1) Does a chronic HCV infection affect the brain? (2) What is known about the prevalence, course, and neurobiology of IFN-α
HCV and the brain
Psychiatric co-morbidity has been reported to occur frequently in patients with chronic HCV infection, with a higher incidence of depressive symptoms, bipolar symptoms, anxiety, fatigue, psychotic symptoms, alcoholism, and drug abuse (Fig. 1). Cognitive disturbances have also been frequently reported [8], [9], [10], [11], [12].The higher rate of psychiatric disorders in HCV infected populations may be related to a higher risk of HCV infection in psychiatric patients but may also be the
Conflict of interest
Financial support for research and/or speaker fees have been received from the following:
Crisanto Diez-Quevedo: Roche Farma Spain, Lundbeck; Carmine M. Pariante: Roche, Lilly; Martin Schaefer: Roche Germany, Lundbeck, Janssen, BMS, Astra Zeneka; Astrid Friebe, Lucile Capuron, Sergio Neri, and Achim Kautz: nil; Geert Robaeys: Merck, Janssen; Graham R. Foster: Roche, Merck, BMS, Janssen, BI, Gilead, Novartis, and Chughai; Daniel Forton: Roche, MSD, Bristol-Myers Squibb, Gilead, Janssen.
Acknowledgements
We thank ELPA and EASL for their support to organise the expert meeting and to present and discuss the results.
References (148)
- et al.
Interferon alpha (IFNalpha) and psychiatric syndromes: a review
Prog Neuropsychopharmacol Biol Psychiatry
(2002) - et al.
Cerebral immune activation in chronic hepatitis C infection: a magnetic resonance spectroscopy study
J Hepatol
(2008) - et al.
Neuropsychological impairment in patients with chronic hepatitis C
Hepatology
(2002) - et al.
Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy
J Hepatol
(2004) - et al.
High prevalence and coinfection rate of hepatitis G and C infections in intravenous drug addicts
J Hepatol
(1997) - et al.
Psychiatric disorders among veterans with hepatitis C infection
Gastroenterology
(2002) - et al.
Emotional state, coping styles, and somatic variables in patients with chronic hepatitis C
Psychosomatics
(2000) - et al.
Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C
J Hepatol
(2002) - et al.
Depression, fatigue, and functional disability in patients with chronic hepatitis C
J Psychosom Res
(2000) - et al.
Musculoskeletal pain and fatigue are associated with chronic hepatitis C: a report of 239 hepatology clinic patients
Am J Gastroenterol
(1999)
Health-related quality of life and depression in patients with chronic hepatitis C
Arch Med Res
Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease
Hepatology
Evidence for a cerebral effect of the hepatitis C virus
Lancet
Cerebral immune activation in chronic hepatitis C infection: a magnetic resonance spectroscopy study
J Hepatol
Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups
Hepatology
Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions
Neuropsychopharmacology
Immune system to brain signaling: neuropsychopharmacological implications
Pharmacol Ther
Effect of single intracerebroventricular injection of alpha-interferon on monoamine concentrations in the rat brain
Eur Neuropsychopharmacol
Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats: role of nitric oxide as a signal crossing the blood–brain barrier
Brain Res
Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain
Brain Res
Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms
Biol Psychiatry
Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy
Brain Behav Immun
Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C
Gastroenterology
Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels
Biol Psychiatry
Association between apolipoprotein E epsilon4 and neuropsychiatric symptoms during interferon alpha treatment for chronic hepatitis C
Psychosomatics
Cytokine-induced depression during IFN-alpha treatment: the role of IL-6 and sleep quality
Brain Behav Immun
Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment
Biol Psychiatry
Psychosocial issues and mental health treatment recommendations for patients with hepatitis C
Psychosomatics
Development and reliability of the HAM-D/MADRS interview: an integrated depression symptom rating scale
Psychiatry Res
Need-adapted HCV-treatment setting for injection drug users
Lancet
Treating hepatitis C in methadone maintenance patients: an interim analysis
Drug Alcohol Depend
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
Lancet
Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C
J Hepatol
Plasma levels of citalopram in depressed patients with hepatitis C
Psychosomatics
Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review
Am J Psychiatry
Suicide risk in hepatitis C and during interferon-alpha therapy: a review and clinical update
J Viral Hepat
Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction
J Clin Psychiatry
Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C – a critical review
Int J Methods Psychiatr Res
Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C
Hepatology
Management of hepatitis C virus infection
J Hepatol
Evidence for neuroinflammation and neuroprotection in HCV infection-associated encephalopathy
Gut
Investigating health-related quality of life, mood and neuropsychological test performance in a homogeneous cohort of Irish female hepatitis C patients
J Viral Hepat
Prevalence of hepatitis C among psychiatric patients in the public sector
Am J Psychiatry
Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management
Drugs
Epidemiology of hepatitis C in the United States
Am J Med
Hepatitis C and depression
Depress Anxiety
Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans
J Viral Hepat
Physician-patient relationship and disclosure behaviour in chronic hepatitis C in a group of German outpatients
Eur J Gastroenterol Hepatol
Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy
Clin Pract Epidemiol Ment Health
Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis
Hepatology
Cited by (177)
Major Depressive Disorder in an International Multisite Wilson Disease Registry
2023, Journal of the Academy of Consultation-Liaison PsychiatryPrevalence of hepatitis C virus infection in patients with chronic mental disorders: The relevance of dual disorders
2023, Gastroenterologia y HepatologiaIs depression the missing link between inflammatory mediators and cancer?
2022, Pharmacology and TherapeuticsMental Illness in Adults With HIV and HCV Infection: Indian Health Service, 2001–2020
2022, American Journal of Preventive MedicineGut-derived systemic inflammation as a driver of depression in chronic liver disease
2022, Journal of Hepatology